dioxins (PCDDs), dibenzofurans (PCDFs), and dioxin-like polychlorinated biphenyls (PCBs) that the authors propose for use in human, fish, and wildlife risk assessment. Given certain simplifying assumptions, TEFs allow one to estimate the toxicity of mixtures of these compounds by the simple addition of compound-specific contributions, expressed in terms of equivalently toxic concentrations (TEQs) of 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD), the most potent of the known aryl hydrocarbon (Ah) receptor ligands. Van den Berg et al. (1) describe each TEF as "an order of magnitude estimate of the toxicity of a compound relative to TCDD" that was "derived by a consensus of experts" (the authors) "using careful scientific judgment after considering all available scientific data." 'While their report reviews several sources of uncertainty "that could compromise the TEF concept," including "nonadditive interactions, differences in shape of the dose-response curve, and species responsiveness," it concludes that it is unlikely for the use of this additive model to result in a great deal of error in predicting the concentrations of TCDD TEQs or responses at environmentally relevant levels due to nonadditive interactions.
The phrase "unlikely to result in a great deal of error" is the only uncertainty characterization that Van Except in a few cases where TEFs were derived from a single REP (e.g., the bird TEFs for the PCBs 105, 126, 156, 157, 167, and 169) , the end point-specific REP data that were considered by Van den Berg et al. (1) "the database is said to be available." The database was available directly after the WHO TEF meeting that was held in June 1997. Requests were received from several people, and all of them received the data.
Regarding their comment on the requirement of "parallelism of doseresponse curves across end points" Starr et al. apparently failed to understand that the cascade of events following binding to the Ah receptor is different for each end point, which might thus result in different dose-response curves. Basic pharmacology and endocrinology have shown that multiple responses mediated by the same receptor mechanism do not have to have parallel dose-response curves because binding to a receptor is but the first step in the cascade of responses. Thus, per definition, the dose-response curves for different health end points cannot be expected to be parallel. This is one of the inherent uncertainties in the derivation of TEFs, but this is well recognized and covered adequately by Van den Berg et al. (1) . Parallel dose-response curves are required for different congeners examining the same response, but this has been amply demonstrated in the literature for various dioxins, furans, and PCBs for various responses, and it was adequately covered by Van I could fill many pages with accounts of encounters with some these dangerous frauds, and over the years I have written several articles on the topic of scaremongering in the food industry (2-4). I am old (81) and long retired (since 1982) , and I profoundly hope that sometime soon a publication such as EHP will give the same concern to this scandal as you would to any other virulent epidemic.
Thank you for this chance to blow off some steam.
